UBS Group
ENZY

UBS Group’s Enzymotec Ltd ENZY Stock Holding History

UBS Group’s Portfolio ENZY Stock Details ENZY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-1,935
Closed -$22K – 8359
2017
Q3 		$22K Sell
1,935
-1,136
-37% -$11.2K ﹤0.01% 6395
2017
Q2 		$25K Buy
3,071
+2,571
+514% +$21.4K ﹤0.01% 6150
2017
Q1 		$4K Sell
500
-1,243
-71% -$10.5K ﹤0.01% 7132
2016
Q4 		$11K Sell
1,743
-724
-29% -$4.77K ﹤0.01% 6891
2016
Q3 		$18K Buy
2,467
+1,497
+154% +$12K ﹤0.01% 6412
2016
Q2 		$8K Buy
970
+598
+161% +$4.96K ﹤0.01% 6935
2016
Q1 		$3K Sell
372
-1,384
-79% -$12.1K ﹤0.01% 7248
2015
Q4 		$17K Sell
1,756
-4,438
-72% -$42K ﹤0.01% 6931
2015
Q3 		$56K Buy
6,194
+1,919
+45% +$17.1K ﹤0.01% 5741
2015
Q2 		$36K Sell
4,275
-495
-10% -$4.54K ﹤0.01% 6316
2015
Q1 		$35K Sell
4,770
-623
-12% -$4.41K ﹤0.01% 6409
2014
Q4 		$41K Buy
+5,393
New +$39.2K ﹤0.01% 6745

Other funds holding ENZY

PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
DG
Delek Group Herzliya, Israel $2.59B AUM 1.24% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $15.7B AUM 36.4% 1-Year Est. Return
GH
GAM Holding Zurich, Switzerland $1.31B AUM 35.17% 1-Year Est. Return
WIC
Water Island Capital New York $1.08B AUM 105.75% 1-Year Est. Return
CRA
Circle Road Advisors New York $27.7M AUM 35.85% 1-Year Est. Return
WRBC
W.R. Berkley Corp Greenwich, Connecticut $2.18B AUM 13.58% 1-Year Est. Return
GCIA
Gabelli & Co Investment Advisers Rye, New York $688M AUM 63.39% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

UBS Group's ENZY Position: Q4 2017 in Review

UBS Group sold out of Enzymotec Ltd (ENZY) in Q4 2017, closing a stake of 1,935 shares — an estimated $22K sold.

UBS Group first reported a position in ENZY in Q4 2014 and held it in 12 quarters. The position peaked at $56K in Q3 2015. 37 funds tracked by Wall St. Rank hold ENZY as of Q4 2017.

  • UBS Group reported no remaining Enzymotec Ltd position as of Q4 2017 after selling out during the quarter.
  • UBS Group sold 1,935 Enzymotec Ltd shares in Q4 2017, an estimated $22K.
  • UBS Group first reported a position in Enzymotec Ltd in Q4 2014 and held it in 12 quarters.
  • UBS Group's Enzymotec Ltd position peaked at $56K in Q3 2015.
  • 37 funds tracked by Wall St. Rank held Enzymotec Ltd as of Q4 2017.

Based on UBS Group's 13F filing for Q4 2017, filed 14 Feb 2018.